U 995

Drug Profile

U 995

Alternative Names: Shark cartilage-derived angiogenesis inhibitor - Gwo-Chang GMP Pharmaceutical Co.

Latest Information Update: 28 Aug 2002

Price : $50

At a glance

  • Originator Gwo-Chyang GMP Pharmaceutical
  • Class Antineoplastics; Dipeptides
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 10 Mar 1999 New profile
  • 10 Mar 1999 Preclinical development for Cancer in Taiwan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top